Hybridtide Patent Granted

October 10, 2017
Longevity Biotech Granted U.S. Patent Covering Hybridtide Platform Technology for Stabilized Peptide Therapeutics

Longevity Biotech, Inc. (LBT) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,782,454 covering the company's Hybridtide® platform technology.

Continue to news room.

Continue to press release.